VolitionRx Limited (NYSE American: VNRX) announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The assay achieved 97% specificity and identified 86% of lymphoma cases, advancing the development of a blood-based liquid biopsy test for feline cancer.
The technology addresses a significant unmet need in veterinary medicine, where early detection of cancer remains challenging. According to the company, the test represents a substantial commercial opportunity in the growing companion animal oncology market. VolitionRx is working toward product commercialization and expects the publication of the study in a peer-reviewed journal to unlock a $5 million contractual milestone payment.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it develops and commercializes simple, cost-effective blood tests to detect and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with additional offices in the U.S. and London.
For more information, visit the company's website at www.Volition.com. The full press release is available at https://ibn.fm/ARsEY.
